ANP 303
Alternative Names: ANP-303Latest Information Update: 27 Jul 2022
At a glance
- Originator ANP Technologies
- Class Antineoplastics; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Lung cancer
Most Recent Events
- 27 Jul 2022 Phase-I clinical trials in Lung cancer in USA (unspecified route) (ANP Technologies website, July 2022)
- 28 Oct 2020 ANP Technologies enters into a collaboration with an unknown organization for the development of ANP 303 (ANP Technologies website, October 2020)
- 28 Oct 2020 Preclinical trials in Lung cancer in USA (ANP Technologies pipeline, October 2020)